BRPI0906492A2 - antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações - Google Patents

antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações

Info

Publication number: BRPI0906492A2
Authority: BR; Brazil
Prior art keywords: cadherin; antagonists; treatment; methods; joint diseases
Prior art date: 2008-01-11

Application number

BRPI0906492A

Other languages

English (en)

Inventor

James G Mcarthur

Original Assignee

Synovex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-11

Filing date

2009-01-09

Publication date

2015-12-01

2009-01-09 Application filed by Synovex Corp filed Critical Synovex Corp

2015-12-01 Publication of BRPI0906492A2 publication Critical patent/BRPI0906492A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0906492A 2008-01-11 2009-01-09 antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações BRPI0906492A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US1073408P	2008-01-11	2008-01-11
PCT/US2009/000162 WO2009089062A2 (en)	2008-01-11	2009-01-09	Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders

Publications (1)

Publication Number	Publication Date
BRPI0906492A2 true BRPI0906492A2 (pt)	2015-12-01

Family

ID=40602259

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0906492A BRPI0906492A2 (pt)	2008-01-11	2009-01-09	antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações

Country Status (15)

Country	Link
US (4)	US8591888B2 (pt)
EP (2)	EP2242769B1 (pt)
JP (1)	JP5511684B2 (pt)
CN (1)	CN101952316B (pt)
AU (1)	AU2009204467B2 (pt)
BR (1)	BRPI0906492A2 (pt)
CA (1)	CA2711394A1 (pt)
DK (1)	DK2242769T3 (pt)
ES (1)	ES2611102T3 (pt)
HU (1)	HUE031207T2 (pt)
IL (1)	IL206880A (pt)
MX (1)	MX2010007551A (pt)
PL (1)	PL2242769T3 (pt)
SI (1)	SI2242769T1 (pt)
WO (1)	WO2009089062A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009089062A2 (en)	2008-01-11	2009-07-16	Synovex Corporation	Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
US8877188B2 (en)	2010-05-04	2014-11-04	The Brigham And Women's Hospital, Inc.	Detection and treatment of non-dermal fibrosis
EP2566967B1 (en) *	2010-05-04	2016-07-06	The Brigham and Women's Hospital, Inc.	Cadherin-11 antagonist for the treatment of fibrosis
JP5886283B2 (ja) *	2010-07-15	2016-03-16	アドヘロンセラピューティクス，インコーポレイテッド	カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法
CN107596518B (zh)	2012-02-29	2021-04-23	普马特里克斯营业公司	可吸入干粉剂
KR20130142025A (ko) *	2012-06-18	2013-12-27	한국생명공학연구원	카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
WO2016100301A1 (en)	2014-12-15	2016-06-23	The Brigham And Women's Hospital, Inc.	Use of cadherin-11 antagonists to treat obesity-associated conditions and other metabolic disorders
EP3302530B1 (en) *	2015-05-29	2022-05-25	Children's Hospital Medical Center	Cdh26 based therapeutic agents and their use
KR101654526B1 (ko) *	2015-10-19	2016-09-06	한국생명공학연구원	카드헤린―１１ 단백질의 발현 또는 활성 억제제를 포함하는 대장암 치료 또는 전이 억제용 약학적 조성물
US10821094B2 (en)	2016-01-13	2020-11-03	Children's Hospital Medical Center	Compositions and methods for treating allergic inflammatory conditions
US11859250B1 (en)	2018-02-23	2024-01-02	Children's Hospital Medical Center	Methods for treating eosinophilic esophagitis

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8323A (en) *		1851-08-26		colne
US248220A (en) *		1881-10-11		Machine for graining and dicing leather
US253200A (en) *		1882-02-07		Timothy guilford
US248219A (en) *		1881-10-11		Panorama-toy
US110755A (en) *		1871-01-03		Improvement in spike-machines
US229199A (en) *		1880-06-22		Wood-working machine
US215482A (en) *		1879-05-20		Improvement in spring be d-bottoms
US229811A (en) *		1880-07-13		dtjnlop
US96746A (en) *		1869-11-09		Improvement in mechanical movements
US4172124A (en)	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
WO1987001130A1 (en)	1985-08-15	1987-02-26	Stauffer Chemical Company	Tryptophan producing microorganism
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5475096A (en)	1990-06-11	1995-12-12	University Research Corporation	Nucleic acid ligands
EP1586635A1 (de)	1990-06-28	2005-10-19	Hoechst Aktiengesellschaft	Fusionsproteine mit Immunglobulinanteilen, ihre Herstellung und Verwendung
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5440021A (en)	1991-03-29	1995-08-08	Chuntharapai; Anan	Antibodies to human IL-8 type B receptor
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0605522B1 (en)	1991-09-23	1999-06-23	Medical Research Council	Methods for the production of humanized antibodies
DE614989T1 (de)	1993-02-17	1995-09-28	Morphosys Proteinoptimierung	Verfahren für in vivo Selektion von Ligandenbindende Proteine.
CU22584A1 (es)	1995-11-17	1999-11-03	Centro Inmunologia Molecular	Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
US5859136A (en) *	1997-11-03	1999-01-12	E. I. Du Pont De Nemours And Company	Coating composition containing an amine functional dispersed polymer and an isocyanate curing agent
US7481999B2 (en) *	1998-05-05	2009-01-27	Adherex Technologies, Inc.	Compounds and methods for modulating OB-cadherin-mediated function
US6472367B1 (en) *	1998-05-05	2002-10-29	Adherex Technologies, Inc.	Compounds and methods for modulating OB-cadherin mediated cell adhesion
US6638911B1 (en) *	1998-05-05	2003-10-28	Adherex Technologies Inc.	Compounds and methods for modulating desmosomal cadherin-mediated functions
EP1075494A2 (en) *	1998-05-05	2001-02-14	Adherex Technologies, Inc.	Compounds and methods for modulating nonclassical cadherin-mediated functions
US6680175B2 (en) *	1998-05-05	2004-01-20	Adherex Technologies, Inc.	Methods for diagnosing and evaluating cancer
US6787136B1 (en) *	1999-09-03	2004-09-07	The Brigham And Women's Hospital, Inc.	Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
PT1207905E (pt) *	1999-09-03	2010-12-07	Brigham & Womens Hospital	Métodos e composições para o tratamento de doença inflamatória utilizando agentes moduladores da caderina-11
US20040110755A1 (en) *	2002-08-13	2004-06-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
AU2003298475A1 (en) *	2002-11-14	2004-06-18	Adherex Technologies, Inc.	Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US6952969B2 (en) *	2003-09-30	2005-10-11	The Aerospace Corporation	Ceramic ball bearing fracture test method
EP1853255A4 (en) *	2005-02-22	2009-07-08	Gemin X Pharmaceuticals Canada	METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
WO2009089062A2 (en) *	2008-01-11	2009-07-16	Synovex Corporation	Cadherin-11 ecl domain antagonists for treating inflammatory joint disorders
US20100322926A1 (en)	2008-02-11	2010-12-23	Novartis Ag	Methods of using cadherin 11 (cdh11) antagonists
WO2010126137A1 (ja) *	2009-05-01	2010-11-04	国立大学法人東京大学	抗カドヘリン抗体
JP5886283B2 (ja)	2010-07-15	2016-03-16	アドヘロンセラピューティクス，インコーポレイテッド	カドヘリン−１１のｅｃ１ドメインを標的とするヒト化抗体ならびに関連組成物および方法

2009
- 2009-01-09 WO PCT/US2009/000162 patent/WO2009089062A2/en active Application Filing
- 2009-01-09 MX MX2010007551A patent/MX2010007551A/es active IP Right Grant
- 2009-01-09 US US12/811,921 patent/US8591888B2/en active Active
- 2009-01-09 SI SI200931574T patent/SI2242769T1/sl unknown
- 2009-01-09 BR BRPI0906492A patent/BRPI0906492A2/pt not_active IP Right Cessation
- 2009-01-09 EP EP09700394.1A patent/EP2242769B1/en active Active
- 2009-01-09 PL PL09700394T patent/PL2242769T3/pl unknown
- 2009-01-09 ES ES09700394.1T patent/ES2611102T3/es active Active
- 2009-01-09 CN CN200980101955.3A patent/CN101952316B/zh active Active
- 2009-01-09 HU HUE09700394A patent/HUE031207T2/hu unknown
- 2009-01-09 CA CA2711394A patent/CA2711394A1/en not_active Abandoned
- 2009-01-09 EP EP16194905.2A patent/EP3181588A1/en not_active Withdrawn
- 2009-01-09 DK DK09700394.1T patent/DK2242769T3/en active
- 2009-01-09 JP JP2010542284A patent/JP5511684B2/ja active Active
- 2009-01-09 AU AU2009204467A patent/AU2009204467B2/en not_active Ceased
- 2009-04-22 US US12/427,993 patent/US7972846B2/en active Active
2010
- 2010-07-08 IL IL206880A patent/IL206880A/en not_active IP Right Cessation
- 2010-07-15 US US12/837,110 patent/US20110045003A1/en not_active Abandoned
2013
- 2013-11-01 US US14/070,106 patent/US9315568B2/en active Active

Also Published As

Publication number	Publication date
SI2242769T1 (sl)	2017-02-28
EP2242769B1 (en)	2016-11-02
IL206880A0 (en)	2010-12-30
MX2010007551A (es)	2010-11-30
PL2242769T3 (pl)	2017-06-30
EP2242769A2 (en)	2010-10-27
AU2009204467A1 (en)	2009-07-16
US7972846B2 (en)	2011-07-05
US8591888B2 (en)	2013-11-26
US20090253200A1 (en)	2009-10-08
US9315568B2 (en)	2016-04-19
DK2242769T3 (en)	2017-02-06
CN101952316A (zh)	2011-01-19
IL206880A (en)	2014-12-31
EP3181588A1 (en)	2017-06-21
CN101952316B (zh)	2015-04-01
ES2611102T3 (es)	2017-05-04
WO2009089062A2 (en)	2009-07-16
AU2009204467B2 (en)	2012-09-06
HUE031207T2 (hu)	2017-07-28
US20110008323A1 (en)	2011-01-13
US20140120104A1 (en)	2014-05-01
JP5511684B2 (ja)	2014-06-04
CA2711394A1 (en)	2009-07-16
WO2009089062A3 (en)	2009-09-24
US20110045003A1 (en)	2011-02-24
WO2009089062A8 (en)	2010-09-02
JP2011509094A (ja)	2011-03-24

Publication	Publication Date	Title
BRPI0906492A2 (pt)	2015-12-01	antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações
ES2525801T8 (es)	2018-03-20	Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
BRPI0916862A2 (pt)	2016-02-10	compostos úteis para o tratamento de doenças degenerativas e inflamatórias
BRPI1012116A2 (pt)	2016-03-15	composição farmacêutica para o tratamento de doenças cardíacas
BRPI0813725A2 (pt)	2014-12-30	Métodos e composições para tratamento de doenças
BRPI0908026A2 (pt)	2015-07-21	Métodos para o tratamento de doenças do intestino
BRPI1015569A2 (pt)	2016-08-16	compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI1014759A2 (pt)	2016-04-19	composto útil para o tratamento de doenças degenerativas e inflamatórias
BRPI0919920A2 (pt)	2016-02-16	compostos para tratamento de doenças e desordens oftálmicas
BRPI0908276A2 (pt)	2015-08-18	Métodos de tratar dor inflamatória
BRPI0813000A2 (pt)	2014-12-23	Composições terapêuticas e uso das mesmas
BR112013011567A2 (pt)	2016-08-09	pontes e superestruturas dentárias e método para fabricação das mesmas
BRPI0812755A2 (pt)	2014-09-30	Compostos de derivados de fenil alquinila para tratar doenças, e desordens oftálmicas
BR112012001344A2 (pt)	2016-03-15	derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças
BRPI0815551A2 (pt)	2015-02-18	Tratamento através de hucbc de doença beta-amiloide
BRPI0911577A2 (pt)	2016-01-05	derivados espiro-indol para o tratamento de doenças parasíticas.
BR112012002265A2 (pt)	2016-06-14	composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
EP2021016A4 (en)	2010-02-24	CXCL13 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
HK1132919A1 (en)	2010-03-12	Use of chitosans for the treatment of nail inflammatory diseases
CO6801718A2 (es)	2013-11-29	Composición terapéutica para el tratamiento de glioblastoma
BRPI0816386A2 (pt)	2017-06-13	composições e métodos para tratar doenças e distúrbios imunológicos e inflamatórios
BRPI0818719A2 (pt)	2015-05-05	Composição para o tratamento de doença articular
GB0700972D0 (en)	2007-02-28	Treatment of inflammatory disease
SMT201600041B (it)	2016-02-25	Agenti terapeutici 713
GB0720976D0 (en)	2007-12-05	Treatment of inflammatory disease

Legal Events

Date	Code	Title	Description
2017-06-27	B25D	Requested change of name of applicant approved	Owner name: ADHERON THERAPEUTICS, INC. (US)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-31	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-09-18	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-09-03	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-11-05	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2020-02-27	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2548 DE 05-11-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.